{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:29:23Z","timestamp":1787840963583,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study analyzes adverse event (AE) signals associated with ramucirumab using data from the FDA Adverse Event Reporting System (FAERS) to provide evidence supporting the safety of the drug for clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were extracted from the FAERS database using Open Vigil 2.1. Signal detection was performed using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) methods. AEs were categorized and described using the Preferred Terms (PTs) and System Organ Class (SOC) classifications from the Medical Dictionary for Regulatory Activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1,701 AE reports related to ramucirumab were retrieved. Most reported cases involved male patients (59.79%), most aged 65\u201374 years (25.57%), with Asia being the primary region of report origin (59.08%). Based on the screening criteria, 130 PT signals across 18 SOC categories were identified, of which 72 PTs were not listed in the drug label. Frequently reported and strongly signaled AEs included hypertension, ascites, proteinuria, edema, and neutropenia\u2014events already noted in the prescribing information of the drug. However, additional AEs, such as pyogenic granuloma, brainstem hemorrhage, interstitial lung disease, and peritonitis, which were not included in the labeling, also showed strong signals and warrant further exploration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The commonly reported AEs of ramucirumab observed in real-world data are consistent with those listed on the drug label. Nevertheless, new suspicious AEs were identified. Enhanced clinical vigilance, through pretreatment risk assessment and ongoing posttreatment monitoring, is recommended to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_129_25","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:07:24Z","timestamp":1756998444000},"page":"917-923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacovigilance study of ramucirumab: A safety analysis based on the FDA adverse event reporting system"],"prefix":"10.4103","volume":"21","author":[{"given":"Meijuan","family":"Song","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"R1-20250905","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1248\/bpb.b19-01071","article-title":"Thyroid dysfunction related to the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab: A series of 14 cases and a descriptive study","volume":"43","author":"Dote","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"R2-20250905","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.2147\/CMAR.S216220","article-title":"Ramucirumab, a second-line option for patients with hepatocellular carcinoma: A review of the evidence","volume":"12","author":"De","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R3-20250905","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R4-20250905","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14740338.2018.1506762","article-title":"The safety of ramucirumab for the treatment of colorectal cancer","volume":"17","author":"Noguerido","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R5-20250905","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1111\/1759-7714.15084","article-title":"Delayed esophageal anastomotic complication and ramucirumab therapy: A case report","volume":"14","author":"Roth","year":"2023","journal-title":"Thorac Cancer"},{"key":"R6-20250905","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R7-20250905","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20250905","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf"},{"key":"R9-20250905","first-page":"103","article-title":"A method for retrieval of adverse event terms in clinical trial databases using standardised MedDRA queries","volume":"30","author":"Breder","year":"2016","journal-title":"Pharmaceut Med"},{"key":"R10-20250905","doi-asserted-by":"crossref","first-page":"892503","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"key":"R11-20250905","first-page":"209","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R12-20250905","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4103\/jcrt.jcrt_749_23","article-title":"Exosomes derived from gastric cancer cells promote phenotypic transformation of hepatic stellate cells and affect the malignant behavior of gastric cancer cells","volume":"20","author":"Zhang","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R13-20250905","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/jcrt.jcrt_144_22","article-title":"Evaluation of HLA-DR and HLA-DQ expression in gastric cancer tissues","volume":"20","author":"Jafari","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R14-20250905","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60327-492-0_23","article-title":"Epidemiology of stomach cancer","volume":"472","author":"Brenner","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R15-20250905","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","article-title":"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study","volume":"22","author":"Valle","year":"2021","journal-title":"Lancet Oncol"},{"key":"R16-20250905","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"R17-20250905","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"R18-20250905","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"R19-20250905","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijpharm.2014.11.056","article-title":"Properties of polidocanol foam in view of its use in sclerotherapy","volume":"478","author":"Nastasa","year":"2015","journal-title":"Int J Pharm"},{"key":"R20-20250905","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/jcrt.jcrt_430_24","article-title":"Case report of short term EGFR TKI induced tubulointerstitial nephritis and IgA nephropathy in a patient with advanced non small cell lung cancer","volume":"21","author":"Park","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R21-20250905","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4103\/jcrt.jcrt_2418_24","article-title":"Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR-mutant advanced non-small cell lung cancer","volume":"21","author":"Chen","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R22-20250905","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"R23-20250905","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.4103\/jcrt.jcrt_2235_24","article-title":"Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report","volume":"20","author":"Li","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R24-20250905","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12890-019-0838-2","article-title":"Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer","volume":"19","author":"Hamada","year":"2019","journal-title":"BMC Pulm Med"},{"key":"R25-20250905","first-page":"5525092","article-title":"Vulvar pyogenic granuloma in adult female population: A case report and review of the literature","author":"Mahmoudnejad","year":"2021","journal-title":"Case Rep Urol 2021"},{"key":"R26-20250905","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/1346-8138.14693","article-title":"Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab","volume":"46","author":"Watanabe","year":"2019","journal-title":"J Dermatol"},{"key":"R27-20250905","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.2169\/internalmedicine.6650-20","article-title":"Ramucirumab-related oral pyogenic granuloma: A report of two cases","volume":"60","author":"Aragaki","year":"2021","journal-title":"Intern Med"},{"key":"R28-20250905","first-page":"e15076","article-title":"Osimertinib and ramucirumab induced pyogenic granulomas: A possible synergistic effect of dual oncologic therapy","volume":"13","author":"Daze","year":"2021","journal-title":"Cureus"},{"key":"R29-20250905","doi-asserted-by":"crossref","first-page":"e231464","DOI":"10.1136\/bcr-2019-231464","article-title":"Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment","volume":"12","author":"Ibe","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R30-20250905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2020.0696","article-title":"Multiple cerebral infarction linked to underlying cancer: A review of Trousseau syndrome-related cerebral infarction","volume":"82","author":"Zhen","year":"2021","journal-title":"Br J Hosp Med"},{"key":"R31-20250905","doi-asserted-by":"crossref","first-page":"104891","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104891","article-title":"Trousseau syndrome related cerebral infarction: Clinical manifestations, laboratory findings and radiological features","volume":"29","author":"Bao","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R32-20250905","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"R33-20250905","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14740338.2015.1074677","article-title":"Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: A systematic review and meta-analysis","volume":"14","author":"Abdel-Rahman","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R34-20250905","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1179\/1973947815Y.0000000053","article-title":"Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: A meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2016","journal-title":"J Chemother"},{"key":"R35-20250905","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_129_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:32:33Z","timestamp":1787837553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_129_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_129_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-01-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}